THE LATEST

Read The 2020 Hot Indications List

How can companies determine where to focus as they develop their pipelines and determine new growth opportunities? Kx Advisors’ 2020 Hot Indications List can help. In our 6th annual analysis of global R&D investment, our experts identified the top indications for industry focus.

Download The White Paper

Insights

Explore our thought
leadership

Alzheimer’s Disease Therapeutics and Diagnostics – Parallel Advancements for Patient Care

Featured

Alzheimer’s Disease Therapeutics and Diagnostics – Parallel Advancements for Patient Care

2023 has already been a landmark year in Alzheimer’s disease (AD) therapeutics: lecanemab (Leqembi), co-developed by Biogen and Eisai, received FDA accelerated approval in January, and Phase 3 results for donanemab (Eli Lilly) are expected in 2Q23, with submission for FDA full approval shortly thereafter (accelerated approval was rejected in January).

Avatar photoBob Serrano and Brett Larson

Blogs and publications
by sector

Health Equity: The Kx Research Approach and Case Study

April 27, 2023 • Advanced healthcare treatments require patients to pass through multiple specialists or undergo significant surgical procedures.

Avatar photo
Evelyn Tee and 2 others
Medtech commercialization, pharma commercialization

Evolving Considerations for Segmenting Aesthetic Practices

April 20, 2023 • The global aesthetics market for product sales has more than doubled in the past 10 years, from $6B to $12.5B. Simultaneously, the number of US aesthetics practices has exploded to exceed 40,000 today.

Avatar photo
Bob Serrano and 2 others
Alzheimer’s Disease Therapeutics and Diagnostics – Parallel Advancements for Patient Care

Alzheimer’s Disease Therapeutics and Diagnostics – Parallel Advancements for Patient Care

April 20, 2023 • 2023 has already been a landmark year in Alzheimer’s disease (AD) therapeutics: lecanemab (Leqembi), co-developed by Biogen and Eisai, received FDA accelerated approval in January, and Phase 3 results for donanemab (Eli Lilly) are expected in 2Q23, with submission for FDA full approval shortly thereafter (accelerated approval was rejected in January).

Avatar photo
Bob Serrano and Brett Larson
Women's Health Opportunuty

Women’s Health: The Opportunity in Gynecology and Beyond

March 8, 2023 • Women’s healthcare and FemTech are garnering increasing attention, yet unmet need remains high, leaving opportunity for investment in an area with significant white space for growth.

Avatar photo
Jenna Riffell, PhD and 2 others
Patient Engagement Digital Health Rachael England

For Patient Engagement solutions looking for an exit, 2023 could be their year

February 15, 2023 • After a fraught 2022 that saw a significant slowdown in acquisitions from 2021’s volume and valuation highs, product companies view M&A as a potential strategy in 2023 to enhance their value proposition and achieve efficiencies of scale.

Avatar photo
Rachael England
5 Misconceptions for MedTech Market Access Strategy

5 Misconceptions for MedTech Market Access Strategy

October 19, 2022 • Market access in MedTech is a complex and rapidly evolving environment, with increasingly intense scrutiny on the costs and benefits of new technologies as the pressure on budgets increases globally.

Avatar photo
Jenna Riffell, PhD and Przemek Czerklewicz
Patient Centered Health Equity

Using the Patient Journey to Understand Health Equity Challenges

September 29, 2022 • Unequal healthcare access among different groups leads to less preventative care, and more urgent and intensive procedures. Such disparities in access currently cost the US healthcare system approximately $320 B annually and is projected to grow to as much as $1 trillion annually in 2040.

Avatar photo
Evelyn Tee and 2 others
AACC Kx Advisors

Key Insights & Takeaways: American Association for Clinical Chemistry Annual Scientific Meeting & Clinical Lab Expo

August 23, 2022 • The Clinical Chemistry Annual Meeting did not disappoint with great attendance, engaging talks, and some innovative exhibits. After digesting all our notes (and a bit of Chicago's finest culinary fare) from the busy week, we walked away with five key takeaways.

Avatar photo
Brian McNally, PhD
World Orphan Drug Congress

Rare Disease Drug Development & Commercialization Learnings, Opportunities & Debates at World Orphan Drug Congress USA 2022

July 21, 2022 • The Kx team attended the World Orphan Drug Congress (WODC) in Boston, MA last week and came away energized from three days of sharing ideas, inspirational stories, and panel discussions.

Avatar photo
Jenna Riffell, PhD and Brett Larson

Q&A with Kx: Spotlight on AACC 2022

July 6, 2022 • Before they head off to the Windy City for this year’s AACC Annual Scientific Meeting & Clinical Lab Expo, we asked Bob Serrano and Brian McNally for their insights on what they hope to learn, see, and are excited to discover at this year’s conference.

Avatar photo
Bob Serrano and Brian McNally, PhD

Cell and Gene Therapy: The Next Frontier in Healthcare

June 5, 2022 • Cell and Gene Therapy (CGT) is one of the most promising new frontiers in advanced therapies with the potential for transformational disease-modifying outcomes. We analyze the state of the Cell & Gene Therapy pipeline and technologies driving growth.

Avatar photo
Sean Vander Linde and 2 others

Strategizing for Your First Drug Launch

June 3, 2022 • Strategizing for your First Drug Launch: Supporting late-stage, pre-revenue pharmaceutical companies who are planning to directly commercialize their first product capitalize on these competitive advantages.

Avatar photo
Chris Waybill

Digital Priorities of the C-Suite

March 28, 2022 • Learn how digital health companies enable health system digital transformation while remaining competitive against Big Tech

Avatar photo
Rachael England

Home Dialysis: Unlocking New Opportunities in an Evolving Landscape

February 3, 2022 •

Download Report

Hot Indications List 2021: Hot MOAs

September 30, 2021 •

Download Report

Key Considerations for Rare Disease Due Diligence

July 20, 2021 •

Download Report
Capital Equipment Pricing

Six Considerations to Evolve Your Capital Equipment Pricing Strategy

May 10, 2021 • As the world of capital equipment becomes more innovative, manufacturers must find ways to stay competitive, including alternative pricing models. Learn more about the new models and the key considerations manufacturers must evaluate to determine the right fit.

Avatar photo
Evelyn Tee
Product Launch Forecast

Using Your Product Launch Forecast as a Strategic Tool

April 22, 2021 • Too often commercial planning teams approach revenue forecasting as a required financial exercise rather than a strategic planning activity. Learn how to craft your product launch forecast as a decision-making tool, rather than just a financial tool.

Avatar photo
Brett Larson and David Geschwind
Understanding Cognitive Bias

How Understanding Cognitive Bias Can Drive Patient Volumes

January 6, 2021 • Cognitive biases held by both patients and providers can negatively impact treatment. Read our key takeaways on how these biases can drive patient volumes.

Avatar photo
Evelyn Tee and Christina Wu
Customer Segmentation Graphic

Kx’s Four-Step Customer Segmentation Process

November 9, 2020 • Learn how your team can improve your customer segmentation process by expanding the factors you include in your segmentation

Avatar photo
Evelyn Tee and Chris Waybill

Hot Indications List 2020 – Neurology

October 29, 2020 •

Download Report

Hot Indications List 2020

October 20, 2020 •

Download Report
World Map Showing Why Companies Need Global Strategy

Why Your Orphan Drug Needs A Global Market Access Strategy

July 9, 2020 • An effective market access strategy for orphan drugs must be globally focused and adaptable to different regions to be effective. Our experts dissect the questions and considerations key to building one.

Avatar photo
Jenna Riffell, PhD and Sean Vander Linde
Map Showing COVID-19 Best Strategies For Medical Practices Pain Points and Solutions

How Medical Practices Can Keep Patients Safe: COVID-19 Best Strategies

June 9, 2020 • As COVID restrictions are rolled back, medical practices can implement practices to keep both staff and patients safe. Our experts outline COVID-19 best strategies based on direct feedback from physicians.

Avatar photo
Chris Waybill and Jason Shim
COVID-19 Pipeline Prioritization Business Meeting

How Does COVID-19 Change Clinical Pipeline Prioritization?

May 28, 2020 • Our experts break down both the challenges healthcare organizations face due to COVID-19 and the considerations they must analyze as they assess and adapt their strategic pipeline.

Avatar photo
Brett Larson
Elective Procedures Doctor Putting On Gloves

Elective Procedures After COVID-19: How To Support Rebounding Demand

May 22, 2020 • Our experts dissect elective procedures COVID-19 restrictions and explore how procedure-focused companies can support rebounding demand.

Avatar photo
Jenna Riffell, PhD
COVID 19 Market Research Target Stakeholders

Should You Do Market Research During COVID-19?

April 22, 2020 • Healthcare leaders are asking: is now a good time to do market research given COVID-19? Our experts answer with an enthusiastic yes. Find out what kinds of research to perform and avoid during the pandemic.

Avatar photo
Sean Vander Linde
COVID-19 Product Forecasting Framework Graphic Depicting Trough and Rebound

Adapting In COVID-19: A Product Forecasting Framework

April 13, 2020 • With patients depending on healthcare companies for life-changing medications and devices, accurate forecasting to respond to the evolving COVID-19 challenges is paramount. Our framework can help product teams adjust appropriately.

Avatar photo
Sean Vander Linde and Jenna Riffell, PhD
Launch Planning Framework For Product Managers During COVID-19

3 Questions To Ask For Launch Planning During COVID-19

March 27, 2020 • Pharmaceuticals and medical device companies must act quickly to adapt product launch plans. See our team’s framework for product managers facing this pandemic.

Avatar photo
Evelyn Tee
Graph depicting degree of impact on procedures based on setting and urgency

How Is COVID-19 Impacting Procedure Volume?

March 27, 2020 • Learn how COVID-19 is impacting procedure volume within the orthopedic field and what insights companies in other fields can leverage to adjust their strategic plans.

Avatar photo
Jenna Riffell, PhD

Hot Indications List 2019

July 9, 2019 •

Download Report

Rare Diseases – Patient Advocacy

May 23, 2019 • See how PAGs help patients navigate a complex journey and ultimately seek out life-changing treatments.

Avatar photo
Sean Vander Linde

Rare Diseases – Stakeholder Education

March 21, 2019 • KOLs and COEs are key stakeholders in the rare disease space and should be top of mind for companies looking to enter the space.

Avatar photo
Jenna Riffell, PhD

Rare Diseases – Market Access

February 13, 2019 • Learn why a global market access strategy is necessary to maximize the opportunity in rare disease.

Avatar photo
Sean Vander Linde

Developing a Winning Outpatient Strategy

January 25, 2019 •

Download Report

Hot Indications List 2018 – Oncology

June 12, 2018 •

Download Report

Hot Indications List 2018

June 12, 2018 •

Download Report

Hot Indications List 2017 – Oncology

June 7, 2017 •

Download Report

Hot Indications List 2017

February 10, 2017 •

Download Report

Delivering Precision Medicine

September 28, 2016 •

Download Report

2016 Hot Indications Deep Dive – Oncology

September 3, 2016 •

Download Report

2016 Hot Indications Deep Dive – Immunology

June 4, 2016 •

Download Report

Hot Indications List 2016

March 1, 2016 •

Download Report

Hot Indications List 2015

March 10, 2015 •

Download Report

Taking a Fresh Look at Co-Pay Assistance Programs

September 3, 2014 •

Download Report